Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triesence via microneedle in non-infectious uveitis
NCT01789320Phase 2Completed
- Sponsor
- Clearside Biomedical
- Start
- Feb 2013
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triamcinolone acetonide in noninfectious uveitis (NIU), intermediate uveitis (IU), posterior uveitis and 1 more, sponsored by Clearside Biomedical. Primary endpoints: Intraocular Pressure at 8 weeks and Best Corrected Visual Acuity at 26 weeks. Started Feb 2013; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
noninfectious uveitis (NIU)intermediate uveitis (IU)posterior uveitispanuveitis
Beyond the preview
Go deeper on NCT01789320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01789320.